838858-06-3

Upstream product

• 838858-05-2 2-(5-fluoro-2,3-bis{[2-(methyloxy)ethyl]oxy}phenyl)-3-oxobutanenitrile 
• 2411-83-8 methyl-2,3-dihydroxybenzoate 
• 838857-98-0 methyl 3-hydroxy-2-{[2-(methyloxy)ethyl]oxy}-5-nitrobenzoate 
• 838858-01-8 methyl 5-fluoro-2,3-bis{[2-(methyloxy)ethyl]oxy}benzoate 
• 838858-03-0 1-(chloromethyl)-5-fluoro-2,3-bis{[2-(methyloxy)ethyl]oxy}benzene 
• 838858-04-1 (5-fluoro-2,3-bis{[2-(methyloxy)ethyl]oxy}phenyl)acetonitrile 
• 838857-96-8 methyl 2-{[2-(methyloxy)ethyl]oxy}-3-[(phenylcarbonyl)oxy]benzoate 
• 838858-00-7 methyl 5-amino-2,3-bis{[2-(methyloxy)ethyl]oxy}benzoate 
• 838857-99-1 methyl 2,3-bis{[2-(methyloxy)ethyl]oxy}-5-nitrobenzoate 
• 838857-97-9 methyl 2-{[2-(methyloxy)ethyl]oxy}-5-nitro-3-[(phenylcarbonyl)oxy]benzoate 
• 221684-52-2 methyl 3-benzoyloxy-2-hydroxybenzoate 

Downstream Products

• 838857-95-7 2-chloro-4-(6-fluoro-1-methyl-8,9-bis{[2-(methyloxy)ethyl]oxy}-3H-pyrazolo[3,4-c]isoquinolin-5-yl)phenol hydrochloride 

Relevant academic research and scientific papers

ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE

The present invention comprises compounds and pharmaceutical compositions comprising the compounds that are inhibitors of ALK. The invention also comprises methods of using the compounds and compositions to treat diseases mediated by ALK, including diseases such as cancer, immunological disorders, cardiovascular diseases, and other degenerative disorders.